Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy

The original publication is available at www.springerlink.comArticleJOURNAL OF GASTROENTEROLOGY. 41(8): 785-790 (2006)journal articl

Nucleotide mutations associated with hepatitis B e antigen negativity

Copyright © 2005 Wiley-Liss, Inc., A Wiley CompanyArticleJOURNAL OF MEDICAL VIROLOGY. 76(2): 170-175 (2005)journal articl

Patients with and without loss of hepatitis B virus DNA after hepatitis B e antigen seroconversion have different virological characteristics

Copyright © 2006 Wiley-Liss, Inc., A Wiley CompanyArticleJOURNAL OF MEDICAL VIROLOGY. 78(1): 68-73 (2006)journal articl

Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection

The definitive version is available at www.blackwell-synergy.com.ArticleJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. 20(11): 1726-1730 (2005)journal articl

Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region

The definitive version is available at www.blackwell-synergy.com.ArticleEUROPEAN JOURNAL OF HAEMATOLOGY. 77(3): 255-258 (2006)journal articl

Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection

The definitive version is available at www.blackwell-synergy.com.ArticleJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. 20(11): 1726-1730 (2005)journal articl

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

ArticleHEPATOLOGY RESEARCH. 32(3): 173-184 (2005)journal articl

The Significance of Enzyme Immunoassay for the Assessment of Hepatitis B Virus Core-Related Antigen following Liver Transplantation

Purpose Recently, a new enzyme immunoassay for the detection of hepatitis B virus (HBV) core-related antigen (HBcrAg) has been reported. In this study, we proposed to account for feasibility of HBcrAg assay, and discuss the dynamics of HBV seen in patients following HBV-related living donor liver transplantation (LDLT). Methods and results This study involved 12 patients; 11 patients had positive serum HBcrAg, and 6 patients had negative HBV-DNA. In the post-operation period, all cases were negative for HBV-DNA and HBsAg in sera under prophylaxis therapy. At post-operation, 5 of the 12 had positive serum HBcrAg, and at stable state, 6 had positive serum HBcrAg postoperatively. The mean levels of HBcrAg following LDLT were significantly lower than those seen in the preoperative-operation stage. Conclusion This enzyme immunoassay is a readily utilizable marker of HBV replication in the post transplantation stage. Furthermore, the evaluation of HBV activity by HBcrAg assay must be studied to determine the appropriate prophylaxis for controlling replication of HBV following LDLT